Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists search for keys to unlock immune attack on rare adrenal cancer

NCT ID NCT00457587

Knowledge-focused Sponsor: University of Wuerzburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is not testing a new drug, but rather doing the early science needed to develop one. Researchers are looking for the right targets (antigens) on adrenocortical carcinoma cells and studying how the tumor suppresses the immune system. The goal is to find a way to create a vaccine or immunotherapy for this rare and aggressive cancer. The study includes 150 people with the cancer and healthy volunteers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify targets for a future vaccine or immunotherapy for adrenocortical carcinoma.
What could go wrong
This is a very early, preclinical study. It is not testing a treatment on patients, so it may not lead to a usable therapy. The findings may not translate into clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Sep 2005

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adrenocortical carcinoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with histological proven adrenocortical carcinoma * healthy persons as control group * Life expectancy \> 6 months Exclusion Criteria: * autoimmune diseases * severe clinical condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenocortical carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenocortical carcinoma Cushing's syndrome

Contacts and locations

Locations

  • Dept. of Medicine I, University of Wuerzburg

    Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.